Literature DB >> 34244611

Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression.

L C Stetson1,2, Dheepa Balasubramanian1, Susan Pereira Ribeiro1, Tammy Stefan1, Kalpana Gupta1, Xuan Xu1, Slim Fourati1, Anne Roe1, Zachary Jackson1, Robert Schauner1, Ashish Sharma1, Banumathi Tamilselvan1, Samuel Li3, Marcos de Lima2,4, Tae Hyun Hwang5, Robert Balderas6, Yogen Saunthararajah2,7, Jaroslaw Maciejewski2,7, Thomas LaFramboise2,3, Jill S Barnholtz-Sloan2,8, Rafick-Pierre Sekaly1,2, David N Wald9,10,11.   

Abstract

The prognosis of most patients with AML is poor due to frequent disease relapse. The cause of relapse is thought to be from the persistence of leukemia initiating cells (LIC's) following treatment. Here we assessed RNA based changes in LICs from matched patient diagnosis and relapse samples using single-cell RNA sequencing. Previous studies on AML progression have focused on genetic changes at the DNA mutation level mostly in bulk AML cells and demonstrated the existence of DNA clonal evolution. Here we identified in LICs that the phenomenon of RNA clonal evolution occurs during AML progression. Despite the presence of vast transcriptional heterogeneity at the single cell level, pathway analysis identified common signaling networks involving metabolism, apoptosis and chemokine signaling that evolved during AML progression and become a signature of relapse samples. A subset of this gene signature was validated at the protein level in LICs by flow cytometry from an independent AML cohort and functional studies were performed to demonstrate co-targeting BCL2 and CXCR4 signaling may help overcome therapeutic challenges with AML heterogeneity. It is hoped this work will facilitate a greater understanding of AML relapse leading to improved prognostic biomarkers and therapeutic strategies to target LIC's.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34244611      PMCID: PMC8807029          DOI: 10.1038/s41375-021-01338-7

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   12.883


  82 in total

1.  Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing.

Authors:  Mei-Chong Wendy Lee; Fernando J Lopez-Diaz; Shahid Yar Khan; Muhammad Akram Tariq; Yelena Dayn; Charles Joseph Vaske; Amie J Radenbaugh; Hyunsung John Kim; Beverly M Emerson; Nader Pourmand
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-22       Impact factor: 11.205

2.  The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.

Authors:  Hamid Bolouri; Jason E Farrar; Timothy Triche; Rhonda E Ries; Emilia L Lim; Todd A Alonzo; Yussanne Ma; Richard Moore; Andrew J Mungall; Marco A Marra; Jinghui Zhang; Xiaotu Ma; Yu Liu; Yanling Liu; Jaime M Guidry Auvil; Tanja M Davidsen; Patee Gesuwan; Leandro C Hermida; Bodour Salhia; Stephen Capone; Giridharan Ramsingh; Christian Michel Zwaan; Sanne Noort; Stephen R Piccolo; E Anders Kolb; Alan S Gamis; Malcolm A Smith; Daniela S Gerhard; Soheil Meshinchi
Journal:  Nat Med       Date:  2017-12-11       Impact factor: 53.440

Review 3.  Potential role of Anxa1 in cancer.

Authors:  Chunmei Guo; Shuqing Liu; Ming-Zhong Sun
Journal:  Future Oncol       Date:  2013-11       Impact factor: 3.404

4.  GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation.

Authors:  Kalpana Gupta; Tammy Stefan; James Ignatz-Hoover; Stephen Moreton; Gary Parizher; Yogen Saunthararajah; David N Wald
Journal:  Cancer Res       Date:  2016-03-10       Impact factor: 12.701

5.  Stem cell gene expression programs influence clinical outcome in human leukemia.

Authors:  Kolja Eppert; Katsuto Takenaka; Eric R Lechman; Levi Waldron; Björn Nilsson; Peter van Galen; Klaus H Metzeler; Armando Poeppl; Vicki Ling; Joseph Beyene; Angelo J Canty; Jayne S Danska; Stefan K Bohlander; Christian Buske; Mark D Minden; Todd R Golub; Igor Jurisica; Benjamin L Ebert; John E Dick
Journal:  Nat Med       Date:  2011-08-28       Impact factor: 53.440

Review 6.  Leukemic stem cells: identification and clinical application.

Authors:  Diana Hanekamp; Jacqueline Cloos; Gerrit Jan Schuurhuis
Journal:  Int J Hematol       Date:  2017-03-29       Impact factor: 2.490

7.  The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.

Authors:  Peter G Smith; Fengfei Wang; Kathryn N Wilkinson; Kerry J Savage; Ulf Klein; Donna S Neuberg; Gideon Bollag; Margaret A Shipp; Ricardo C T Aguiar
Journal:  Blood       Date:  2004-08-26       Impact factor: 22.113

Review 8.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

9.  Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway.

Authors:  Xiao-Lin Lin; Qi Xu; Lei Tang; Li Sun; Ting Han; Li-Wei Wang; Xiu-Ying Xiao
Journal:  PLoS One       Date:  2017-05-10       Impact factor: 3.240

View more
  6 in total

Review 1.  Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents.

Authors:  Adriane Halik; Christopher Maximilian Arends; Lars Bullinger; Frederik Damm; Mareike Frick
Journal:  Cancers (Basel)       Date:  2022-03-26       Impact factor: 6.639

2.  Targeting IL8 as a sequential therapy strategy to overcome chemotherapy resistance in advanced gastric cancer.

Authors:  Huning Jiang; Jiahua Cui; Hao Chu; Tingting Xu; Mengyan Xie; Xinming Jing; Jiali Xu; Jianwei Zhou; Yongqian Shu
Journal:  Cell Death Discov       Date:  2022-04-29

Review 3.  High-throughput single-сell sequencing in cancer research.

Authors:  Qingzhu Jia; Han Chu; Zheng Jin; Haixia Long; Bo Zhu
Journal:  Signal Transduct Target Ther       Date:  2022-05-03

4.  Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia.

Authors:  Lucia Altucci; Wout Megchelenbrink; Lars Bullinger; Hendrik G Stunnenberg; Yanan Zhai; Prashant Singh; Anna Dolnik; Peter Brazda; Nader Atlasy; Nunzio Del Gaudio; Konstanze Döhner; Hartmut Döhner; Saverio Minucci; Joost Martens
Journal:  Mol Cancer       Date:  2022-08-19       Impact factor: 41.444

5.  Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters.

Authors:  Noortje van Gils; Han J M P Verhagen; Michaël Broux; Tania Martiáñez; Fedor Denkers; Eline Vermue; Arjo Rutten; Tamás Csikós; Sofie Demeyer; Meryem Çil; Marjon Al; Jan Cools; Jeroen J W M Janssen; Gert J Ossenkoppele; Renee X Menezes; Linda Smit
Journal:  iScience       Date:  2022-08-25

6.  Integrating temporal single-cell gene expression modalities for trajectory inference and disease prediction.

Authors:  Jolene S Ranek; Natalie Stanley; Jeremy E Purvis
Journal:  Genome Biol       Date:  2022-09-05       Impact factor: 17.906

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.